Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 61

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 61
---
 Avenue                                         
 Suite 2920                                                   
 Miami, Florida 33131                                         
 E-mail:            thomas@cm-funds.com/jonathan@cm-funds.com 
 Attention:     Thomas Walsh/Jonathan                         
 Juchno                                                       |
| With a copy to (which shall                                  
 not constitute notice or service of process):                |
| Greenberg Traurig, P.A.                                      
 333 S.E. 2nd Avenue, Suite                                   
 4400                                                         
 Miami, Florida 33131                                         
 Attention:     John D. Owens,                                
 III, Esq.                                                    
 E-mail:            jo@gtlaw.com                              |
| If to the Depositary:                                        |
| JPMorgan Chase Bank, N.A.                                    
 383 Madison Avenue, Floor 11                                 
 New York, New York 10179                                     
 Attention: Depositary Receipts Group                         
 E-mail Address: DR_Global_CSM@jpmorgan.com                   |

| -33- |

or at such other address and/or email address
and/or to the attention of such other Person as the recipient party has specified by written notice given to each other party three (3)
Business Days prior to the effectiveness of such change. Written confirmation of receipt (A) given by the recipient of such notice, consent
or other communication, (B) mechanically or electronically generated by the sender’s email account containing the time, date, and
recipient email address, as applicable or (C) provided by a nationally recognized overnight delivery service, shall be rebuttable evidence
of personal service, or receipt from a nationally recognized overnight delivery service in accordance with clause (i), (ii) or (iii) above,
respectively.

(g) . This Agreement shall be binding upon and inure to the benefit of the parties and their respective successors and permitted
assigns. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Investor,
including by merger or consolidation. The Investor may not assign its rights or obligations under this Agreement.

(h) . This Agreement is intended for the benefit of the parties hereto and their respective permitted successors
and assigns and, except as set forth in Section 9 with respect to those persons entitled to indemnity thereunder, is not for the benefit
of, nor may any provision hereof be enforced by, any other Person.

(i) .
The Company shall afford the Investor and its counsel with the opportunity to review and comment upon, shall consult with the